接种 COVID-19 疫苗后因格林-巴利综合征死亡：病例报告。

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL

Clinical Medicine Insights. Case Reports Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI:10.1177/11795476241274692

Antonio Coviello, Carmine Iacovazzo, Maria Vargas, Concetta Posillipo, Francesco Sagnelli, Pasquale Diglio, Dario Cirillo, Giuseppe Servillo

{"title":"接种 COVID-19 疫苗后因格林-巴利综合征死亡：病例报告。","authors":"Antonio Coviello, Carmine Iacovazzo, Maria Vargas, Concetta Posillipo, Francesco Sagnelli, Pasquale Diglio, Dario Cirillo, Giuseppe Servillo","doi":"10.1177/11795476241274692","DOIUrl":null,"url":null,"abstract":"The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient's hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments.. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.","PeriodicalId":10357,"journal":{"name":"Clinical Medicine Insights. Case Reports","volume":"17 ","pages":"11795476241274692"},"PeriodicalIF":0.8000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457283/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report.\",\"authors\":\"Antonio Coviello, Carmine Iacovazzo, Maria Vargas, Concetta Posillipo, Francesco Sagnelli, Pasquale Diglio, Dario Cirillo, Giuseppe Servillo\",\"doi\":\"10.1177/11795476241274692\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient's hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments.. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.\",\"PeriodicalId\":10357,\"journal\":{\"name\":\"Clinical Medicine Insights. Case Reports\",\"volume\":\"17 \",\"pages\":\"11795476241274692\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457283/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights. Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11795476241274692\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795476241274692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

病毒 SARS-CoV-2（严重急性呼吸系统综合症冠状病毒 2）会引起 COVID-19，这是一种可能致命的疾病。COVID-19 疫苗适用于主动免疫，以预防由 SARS-CoV-2 引起的 COVID-19。我们报告了一例 66 岁女性病例，她有高血压和焦虑抑郁综合征病史，在接种 COVID-19 疫苗 4 周后出现吉兰巴雷综合征（GBS）。住院期间，患者接受了高剂量静脉注射免疫球蛋白（IVIG）和血浆置换治疗。尽管接受了治疗，但呼吸功能的恶化导致患者过早死亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report.

The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient's hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments.. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Medicine Insights. Case Reports MEDICINE, GENERAL & INTERNAL-

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

8 weeks